You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

CORRECTION article

Front. Pharmacol., 06 October 2023

Sec. Ethnopharmacology

Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1239060

Corrigendum: Systems pharmacology approach to investigate the mechanism of Kai-Xin-San in Alzheimer’s disease

  • 1. Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China

  • 2. Department of Endocrinology, Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen, China

  • 3. Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, United States

  • 4. Department of Medicine, Harvard Medical School, Boston, MA, United States

  • 5. Department of Clinical Laboratory, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

  • 6. Department of Encephalopathy First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China

  • 7. Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China

Article metrics

View details

2

Citations

1,7k

Views

607

Downloads

In the published article, there was an error in Figure 8 as published. The Iba1 fluorescence image of the cortex and corresponding merged image in the KXS-L group was mistakenly displayed. The corrected Figure 8 and its caption appear below.

FIGURE 8

FIGURE 8

Kai-Xin-San (KXS) attenuates microglia activation in scopolamine (SCOP)-induced mice. Immunofluorescence analysis in the hippocampus (CA1) and cortex. Microglia were stained with anti-Iba-1 (red) and the nuclei were stained with DAPI (blue). Scale bar: 50 mm. Con, control group; SCOP, scopolamine; KXS-L, low-dose Kai-Xin San (1.4 g/kg); KSX-H, high-dose Kai-Xin San (2.8 g/kg); Don, donepezil.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

systems pharmacology, Kai-Xin-San, Alzheimer’s disease, cholinergic system, neuroinflammation

Citation

Luo Y, Li D, Liao Y, Cai C, Wu Q, Ke H, Liu X, Li H, Hong H, Xu Y, Wang Q, Fang J and Fang S (2023) Corrigendum: Systems pharmacology approach to investigate the mechanism of Kai-Xin-San in Alzheimer’s disease. Front. Pharmacol. 14:1239060. doi: 10.3389/fphar.2023.1239060

Received

23 August 2023

Accepted

22 September 2023

Published

06 October 2023

Volume

14 - 2023

Edited and reviewed by

Wei Peng, Chengdu University of Traditional Chinese Medicine, China

Updates

Copyright

*Correspondence: Qi Wang, ; Jiansong Fang, ; Shuhuan Fang,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics